Generic Ethionamide

Order cheap Generic Ethionamide () without dr prescription in the United States

In our USA pharmacy, you can buy Ethionamide without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Ethionamide is a second‑line antituberculous antibiotic used in combination with other agents to treat active tuberculosis (TB) caused by Mycobacterium tuberculosis when first‑line drugs (such as isoniazid or rifampin) cannot be used due to resistance or intolerance. It is a prodrug that must be activated by bacterial enzymes and then inhibits mycolic acid synthesis, a critical step in cell wall formation, thereby exerting a bacteriostatic effect on actively multiplying tubercle bacilli.
Usual adult dose: The standard dose is 15‑20 mg per kilogram of body weight per day, divided into two or three oral doses, with a maximum total daily dose of 1000 mg. A typical adult regimen starts with 250 mg twice daily, and the dose may be increased gradually under close medical supervision.
Dosage form: Oral tablet, 250 mg.
Onset of action: Antimycobacterial activity begins within a few days, but clinical improvement may take several weeks; treatment is typically continued for 18‑24 months as part of a multi‑drug regimen.
Duration of action: Dosed two or three times daily to maintain therapeutic concentrations; the elimination half‑life is approximately 2‑3 hours.
Alcohol consumption must be strictly avoided during therapy because alcohol can potentiate the central nervous system and hepatic side effects of ethionamide, including increased risk of seizures and liver toxicity.
Most common side effects: gastrointestinal intolerance (nausea, vomiting, anorexia, metallic taste), orthostatic hypotension, dizziness, and neurotoxicity (including peripheral neuropathy, which can be prevented by concomitant pyridoxine).
Would you like to try Ethionamide without a prescription?

General Information about Ethionamide

• INN (International Nonproprietary Name): Ethionamide
• Brand names available in the USA: Trecator® (brand discontinued; generic ethionamide tablets are manufactured by various FDA‑approved generic companies, including Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., and others. The active ingredient remains ethionamide, and it is typically referred to by its generic name.)
• ATC code: J04AD03
• Dosage forms and strengths: Sugar‑coated oral tablets containing 250 mg of ethionamide.
• Manufacturers in USA: Generic ethionamide is manufactured and distributed by several companies such as Teva Pharmaceuticals USA, Inc., Mylan Pharmaceuticals Inc., and other FDA‑approved generic manufacturers.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) (NDA 013186).
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Ethionamide is a synthetic isonicotinic acid derivative structurally related to isoniazid. It is a prodrug that enters mycobacterial cells by passive diffusion and is then activated by the bacterial enzyme EthA, a monooxygenase. The active metabolite forms a covalent adduct with nicotinamide adenine dinucleotide (NAD+), which then inhibits the enoyl‑acyl carrier protein reductase InhA, a key enzyme in the fatty acid synthase II system. This inhibition blocks the synthesis of mycolic acids, the long‑chain fatty acids that are essential components of the mycobacterial cell wall. The resulting disruption of cell wall integrity leads to bacteriostasis. Cross‑resistance with isoniazid may occur but is often partial; ethionamide can be effective against some isoniazid‑resistant strains because its activation pathway differs. After oral administration, ethionamide is rapidly and nearly completely absorbed, with peak plasma concentrations occurring within 1‑2 hours. The drug is widely distributed throughout body tissues and fluids, including the cerebrospinal fluid in the presence of inflamed meninges. Metabolism is extensive in the liver, primarily via CYP450 enzymes and flavin‑containing monooxygenase; several metabolites are inactive. Less than 1% is excreted unchanged in urine. The terminal half‑life is approximately 2‑3 hours, necessitating multiple daily doses. Due to frequent gastrointestinal intolerance, gradual dose titration and administration with food are often required.

Indications

• Treatment of active tuberculosis caused by Mycobacterium tuberculosis (including multidrug‑resistant TB) in combination with other antituberculous agents when the organism is resistant to first‑line drugs (isoniazid and rifampin) or when the patient is intolerant to these agents.
• Ethionamide should never be used as monotherapy and must be administered as part of a multi‑drug regimen to prevent the emergence of resistance.

Important Warnings and Precautions

Ethionamide may cause severe, dose‑dependent hepatotoxicity, including hepatitis, jaundice, and fulminant liver failure; liver function tests must be monitored at baseline and monthly during therapy. Peripheral neuropathy and other neurotoxic effects (including optic neuritis, seizures, and encephalopathy) are well‑recognized complications and can be minimized by concurrent administration of pyridoxine (vitamin B6) 50‑100 mg daily. Severe gastrointestinal intolerance (metallic taste, nausea, vomiting, diarrhea) often limits patient compliance; gradual dose escalation and antiemetics may help. Orthostatic hypotension can occur, particularly in patients receiving concomitant medications that lower blood pressure. Hypoglycemia may develop in patients with diabetes mellitus. Blood glucose levels should be monitored, and antidiabetic therapy adjusted accordingly. Hypothyroidism has been reported with prolonged ethionamide therapy, especially when used in combination with para‑aminosalicylic acid (PAS); periodic thyroid function monitoring is recommended. Ethionamide should be used with caution in patients with a history of depression or other psychiatric disorders, as it may exacerbate these conditions. This drug is not intended for monotherapy; it must be used in conjunction with at least two other antituberculous drugs to prevent resistance. Full adherence to the prescribed regimen is essential for treatment success.

At‑risk groups

• Elderly: Elderly patients may be more susceptible to hepatotoxicity, neurotoxicity, and orthostatic hypotension. Initiate at the lower end of the dosing range and monitor closely.
• Pregnancy: There are no adequate studies in pregnant women. Ethionamide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is generally not recommended for use in pregnancy, especially in the first trimester; alternative regimens should be considered if possible. If used, pyridoxine supplementation is essential.
• Breastfeeding: It is not known whether ethionamide is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the mother.
• Renal impairment: No dose adjustment is necessary, but use with caution because metabolites are excreted renally and accumulation has not been studied extensively.
• Hepatic impairment: Contraindicated in patients with severe liver disease; in mild to moderate impairment, use with extreme caution and closely monitor hepatic function.
• Pediatric: Safety and efficacy have not been firmly established in children, but ethionamide is used off‑label in pediatric TB when necessary. Dosing is weight‑based (15‑20 mg/kg/day). Monitoring for neurologic and hepatic toxicity is critical.
• Diabetes mellitus: Blood glucose must be closely monitored; hypoglycemia may occur. Adjust insulin or oral hypoglycemics accordingly.

Driving and alcohol

Ethionamide can cause dizziness, visual disturbances, and postural hypotension, all of which may impair the ability to drive or operate machinery. Patients should not drive or engage in hazardous activities until they know how the medication affects them. Alcohol is strictly prohibited during treatment; it exacerbates the hepatotoxic and neurotoxic effects of ethionamide and may increase the risk of gastrointestinal side effects and seizures.

Dosage Instructions

• Adults: The recommended dose is 15‑20 mg/kg/day, divided into two or three oral doses. A typical starting regimen is 250 mg twice daily (500 mg/day), and the dose is increased gradually over 1‑2 weeks to the target daily dose, usually 500‑1000 mg/day. The maximum daily dose is 1000 mg.
• Children: Dosed at 15‑20 mg/kg/day, in two or three divided doses. For a 20 kg child, the dose would be 300‑400 mg/day, typically given as 125 mg (half a 250 mg tablet) two to three times daily; the tablet is scored and can be split.
• Administration: Tablets should be taken with food or a small snack to reduce gastrointestinal irritation. Swallow the tablet whole with a full glass of water. If necessary, the tablet may be crushed and mixed with a small amount of soft food, but the bitter taste may be unpleasant; follow with juice or water. Pyridoxine (vitamin B6) 50‑100 mg daily is routinely prescribed to prevent or minimize peripheral neuropathy.
• Missed dose: If a dose is missed, take it as soon as possible on the same day. If it is almost time for the next dose, skip the missed dose and continue with the regular schedule. Do not double the dose.

Side Effects and Contraindications

Most common side effects: Gastrointestinal disturbances are the most frequent and often dose‑limiting, including anorexia, nausea, vomiting, epigastric pain, diarrhea, and a persistent metallic taste. These can be reduced by gradual dose titration, taking with food, and antiemetics. Neurologic side effects include peripheral neuropathy (paresthesias, burning feet), dizziness, headache, and drowsiness. Orthostatic hypotension, skin rash, and gynecomastia have also been reported.
Serious adverse reactions: Hepatotoxicity (transaminase elevation, hepatitis, jaundice) occurs in up to 5‑10% of patients; it is usually reversible with dose reduction or drug discontinuation but can be fatal. Severe neurotoxicity such as optic neuritis, encephalopathy, and seizures have been reported. Hypoglycemia may be severe in diabetic patients. Hypothyroidism, especially when used with PAS, may appear after months of therapy.
Absolute contraindications: Known hypersensitivity to ethionamide; severe hepatic impairment; and acute porphyria (ethionamide may precipitate an acute attack).

Drug Interactions

• Alcohol: Contraindicated; increases the risk of liver damage and central nervous system toxicity (seizures).
• Cycloserine and ethambutol: Additive risk of neurologic side effects; caution required.
• Isoniazid: Cross‑resistance is possible but not complete; when used together, neurotoxicity (peripheral neuropathy) is additive, and higher doses of pyridoxine may be necessary.
• Rifampin: May increase the risk of hepatotoxicity; liver function monitoring is imperative.
• Antihypertensives: Additive orthostatic hypotension; monitor blood pressure.
• Insulin and oral hypoglycemics: Ethionamide may enhance their glucose‑lowering effect; monitor blood glucose and adjust doses accordingly.
• Other hepatotoxic drugs (e.g., pyrazinamide, valproic acid): Increased risk of liver injury; avoid if possible or monitor closely.
• Antacids and H2‑blockers: May reduce gastrointestinal absorption; separate dosing by at least 2 hours.

Practical Advice

• Take ethionamide exactly as prescribed, with food to minimize stomach upset. Do not stop taking it, even if you feel better; completing the full course of treatment is crucial.
• Vitamin B6 (pyridoxine) should be taken daily as directed to prevent nerve damage. Do not skip this supplement.
• Avoid all alcohol throughout the treatment period; read labels of over‑the‑counter products to avoid hidden alcohol.
• Rise slowly from sitting or lying positions to prevent dizziness from orthostatic hypotension.
• Report immediately any yellowing of the skin or eyes, dark urine, severe vomiting, numbness or tingling in hands or feet, blurred vision, or confusion.
• Blood tests for liver function, thyroid function, and blood glucose are required periodically; keep all appointments.
• Store at room temperature (20‑25°C / 68‑77°F) away from light and moisture. Keep out of reach of children.
• Never share this medication; it is part of a carefully designed combination regimen for your specific infection.

Alternative Medications

• Prothionamide: A closely related thioamide not marketed in the US but used internationally; similar efficacy and side‑effect profile.
• Linezolid (Zyvox): An oxazolidinone antibiotic that is a key component of multidrug‑resistant TB regimens; may cause bone marrow suppression and neuropathy with prolonged use.
• Clofazimine (Lamprene): A riminophenazine dye active against TB and used in drug‑resistant regimens; side effects include skin discoloration and gastrointestinal upset.
• Bedaquiline (Sirturo): An ATP synthase inhibitor approved for multidrug‑resistant TB; requires ECG monitoring due to QT prolongation.
• Delamanid (Deltyba): Not FDA‑approved; used in other countries for drug‑resistant TB.

Clinical Efficacy

Ethionamide, as part of a multi‑drug regimen, is bacteriostatic against Mycobacterium tuberculosis and is critical for the treatment of multidrug‑resistant TB when first‑line agents are inactive. Clinical data from World Health Organization (WHO)‑recommended long‑term regimens show that inclusion of ethionamide in combination with other second‑line drugs (fluoroquinolones, injectable agents, cycloserine, PAS) achieves culture conversion rates of 65‑80% at 6 months. The drug penetrates well into most tissues, including cerebrospinal fluid, making it useful in TB meningitis. The main limitation is the high frequency of gastrointestinal and neurologic adverse effects, which lead to poor adherence in some patients. Resistance to ethionamide can develop rapidly if used as monotherapy; thus, it is always employed as a component of a directly observed therapy program.

Important:

Ethionamide is a powerful second‑line antituberculous antibiotic that must be used only under the strict supervision of a physician experienced in managing tuberculosis. It must never be taken alone; it is always part of a combination regimen. This drug can cause severe liver damage, which may be fatal; liver function must be monitored before and regularly during treatment. Peripheral neuropathy is common unless pyridoxine (vitamin B6) is taken concurrently. Alcohol is absolutely forbidden during therapy. Ethionamide can cause significant stomach upset, metallic taste, and dizziness. Do not drive or operate heavy machinery until you are certain you are not impaired. If you become pregnant or plan to become pregnant, contact your doctor immediately; this medication is not recommended during pregnancy. Do not skip doses or stop treatment early, as this can lead to drug‑resistant TB. Keep this medication out of the reach of children. The information provided is not a substitute for professional medical advice.

How to buy Generic Ethionamide no prescription U.S. Online Pharmacy